Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer. Patients with locally advanced, unresectable (not able ...

After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer (NSCLC). Using ...

LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have ...

AstraZeneca’s Tagrisso is already swimming in billions in annual sales after setting a new standard for treating metastatic EGFR-mutant non-small cell lung cancer. And now, with an FDA go-ahead in ...

The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 ...

Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...

TAGRISSO ® (osimertinib) 40mg and 80mg once daily oral tablet has been approved in over 45 countries, including the US, EU, Japan and China, for patients with EGFR T790M mutation-positive advanced non ...

AstraZeneca presented data from the AURA3 trial that data is supportive of Tagrisso (osimertinib) potentially becoming the new standard of care for 2nd-line treatment of patients with epidermal growth ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of ...